Advair vs Symbicort (Seroflo vs Foracort): Which Combination Inhaler, and Why Only One Doubles as a Reliever

Advair and Symbicort are the two combination inhalers most people end up choosing between once a plain steroid inhaler stops being enough. Outside the United States the same molecule pairs are sold widely as generics. The two you will see most often are Cipla's Seroflo, which pairs fluticasone with salmeterol exactly as Advair does, and Foracort, which pairs budesonide with formoterol exactly as Symbicort does.

Both combine an inhaled corticosteroid with a long-acting bronchodilator. Both control asthma well when taken every day. On the measures most comparisons stop at, they look interchangeable. They are not, and the difference that matters is not the steroid. It is how quickly the bronchodilator starts to work, because that single property decides whether the inhaler can also be used as a reliever. The reliever question has driven most of the change in asthma guidelines over the last decade.

What is in each inhaler

	Advair pairing	Symbicort pairing
Inhaled corticosteroid	Fluticasone propionate	Budesonide
Long-acting beta-2 agonist	Salmeterol	Formoterol
US and UK brand	Advair (US), Seretide (UK)	Symbicort
Cipla generic	Seroflo	Foracort
Bronchodilator onset	Slow	Within minutes
Usable as a reliever	No	Yes, on a prescribed maintenance and reliever plan

The steroid is the controller. It treats the airway inflammation that keeps asthma active, it produces nothing you can feel in the moment, and it is the component that prevents attacks. The long-acting beta-2 agonist relaxes the muscle around the airways for roughly 12 hours. It improves symptoms and lung function but does not treat the inflammation underneath.

Combining them in one device was as much an adherence decision as a pharmacological one. Adding a long-acting beta agonist to an inhaled steroid gives more benefit than doubling the steroid dose, and a fixed combination performs at least as well as the same two drugs taken from separate inhalers (PMID: 10400406). A single device also means nobody can take the bronchodilator, which they can feel, and quietly skip the steroid, which they cannot.

The one difference that decides the comparison

Formoterol and salmeterol both last about 12 hours. What separates them is onset. In a double-blind crossover study in 28 asthmatic patients, formoterol at 6, 12 and 24 mcg all produced faster bronchodilation than salmeterol 50 mcg when lung function was measured 3 minutes after the dose, while the duration of effect over 12 hours was similar. The same study estimated that salmeterol 50 mcg matched roughly 9 mcg of formoterol in bronchodilating potency (PMID: 9426083).

Put plainly, formoterol behaves like a fast reliever that happens to last all day, and salmeterol behaves like a slow controller that happens to be a bronchodilator. For someone who is short of breath right now, those are very different drugs, even though they sit in the same class on paper.

Why only budesonide with formoterol can double as a reliever

Because formoterol works within minutes, a budesonide and formoterol inhaler can do both jobs: fixed doses morning and evening, plus extra doses of the same inhaler when symptoms appear. This is maintenance and reliever therapy, usually shortened to MART or SMART. Every extra puff taken for symptoms also delivers steroid, so anti-inflammatory treatment rises automatically at the moment the asthma is flaring, which is exactly when it is needed.

A salmeterol and fluticasone inhaler cannot be used this way. Salmeterol is too slow to relieve an attack, and repeated extra doses taken while waiting for relief would stack up a long-acting beta agonist without producing the relief. Anyone on Advair or Seroflo still needs a separate short-acting reliever such as Asthalin (salbutamol) or Levolin (levosalbutamol). How those two compare is covered in our salbutamol and levosalbutamol comparison.

Guidelines on both sides of the Atlantic have moved in this direction. The Global Initiative for Asthma no longer recommends a short-acting reliever on its own at any step and names inhaled corticosteroid with formoterol as the preferred reliever for adults and adolescents (PMID: 38237858). In the United States, the 2020 NAEPP focused update recommends single maintenance and reliever therapy with an inhaled corticosteroid and formoterol for patients aged 4 and over at steps 3 and 4. Neither extends that recommendation to salmeterol combinations. How the regimen works day to day, including the daily ceiling, is set out in our budesonide with formoterol guide.

What the head-to-head trials found

Three sources compare budesonide and formoterol used as maintenance and reliever therapy against fixed-dose salmeterol and fluticasone with a separate reliever.

Source	Design	Result on severe exacerbations
COMPASS (Kuna 2007)	6 months, double-blind, three arms	12 events per 100 patients with maintenance and reliever therapy vs 19 with fixed salmeterol and fluticasone; rate ratio 0.61 (95% CI 0.49 to 0.76)
AHEAD (Bousquet 2007)	6 months, double-blind, 2,309 patients, against high-dose salmeterol and fluticasone 50/500 twice daily	Time to first severe exacerbation not significantly different: risk ratio 0.82 (95% CI 0.63 to 1.05)
Systematic review (2026)	Pooled randomized trials	Against fluticasone and salmeterol with a short-acting reliever: hazard ratio 0.75 for first severe exacerbation, rate ratio 0.72

COMPASS is the strongest single result. Severe exacerbations requiring hospital care, emergency treatment or oral steroids fell by 39 percent against fixed salmeterol and fluticasone, with less total inhaled steroid used, while lung function, asthma control days and quality of life improved to a similar degree in every arm (PMID: 17362472).

AHEAD is the one most summaries leave out, because its primary endpoint missed. Against salmeterol and fluticasone at the highest licensed dose, time to first severe exacerbation was not significantly longer with maintenance and reliever therapy. What AHEAD did show is that daily symptom control was similar while the maintenance and reliever arm used a mean of 792 mcg of budesonide a day against 1,000 mcg of fluticasone. Converted to a common beclometasone scale, that is about 60 percent of the steroid load.

The pooled 2026 review lands between the two: a real advantage in delaying the first severe attack and in the annual rate of attacks, moderate in size (PMID: 42450874).

Reading those trials honestly

Three qualifications belong next to the numbers.

COMPASS and AHEAD were both funded by AstraZeneca, which makes Symbicort. The large safety trial for the Advair pairing was funded by GlaxoSmithKline, which makes Advair. Nobody has run a definitive neutral head-to-head, and industry funding is a reason to read endpoints carefully rather than a reason to dismiss them.

The advantage is in exacerbations, not in day-to-day symptoms. Patients on fixed-dose salmeterol and fluticasone felt about as well week to week. The benefit of maintenance and reliever therapy shows up in attacks that do not happen, which is the outcome that matters most and the one a patient cannot perceive.

The mechanism is timing, not a better steroid. Maintenance and reliever therapy works because it puts steroid into the airways at the start of a flare. Someone whose asthma almost never flares, and who takes a fixed-dose inhaler reliably, gains relatively little by switching.

Steroid dose: the numbers on the box are not comparable

Fluticasone propionate is roughly twice as potent per microgram as budesonide, and the dose bands used by the Global Initiative for Asthma reflect that. The bands describe approximate clinical comparability rather than exact equivalence, but they are the right tool for checking whether a switch between brands has quietly become a change of dose.

Total daily dose, adults and adolescents	Low	Medium	High
Fluticasone propionate (powder or aerosol)	100 to 250 mcg	Above 250 to 500 mcg	Above 500 mcg
Budesonide (dry powder)	200 to 400 mcg	Above 400 to 800 mcg	Above 800 mcg

The practical trap is that the number printed on the pack is a per-dose figure, and the number of doses per day differs by device. A Seroflo 250 aerosol inhaler at two puffs twice daily delivers 1,000 mcg of fluticasone a day, which is a high dose. A Seroflo 250 Rotacap at one capsule twice daily delivers 500 mcg, which is a medium dose. Same name, same number on the box, twice the steroid.

Metered doses, delivered doses and what the labels mean

Two labeling conventions are in use, and they explain most of the confusion when people compare an Indian generic with a US or European brand. Some products state the metered dose, meaning what leaves the valve or capsule. Others state the delivered dose, meaning what leaves the mouthpiece after losses inside the device.

Symbicort Turbuhaler 160/4.5 states the delivered dose and corresponds to a metered 200 mcg of budesonide with 6 mcg of formoterol, which is what Foracort 200 states. Advair HFA 230/21 in the United States likewise states the delivered dose of the aerosol labeled 250/25 as Seretide in the UK and as Seroflo 250. The two numbers describe the same amount of drug.

Product	Per dose	Daily steroid at a common regimen	Band	Price
Seroflo 50 Inhaler	Fluticasone 50 mcg, salmeterol 25 mcg per puff	200 mcg (2 puffs twice daily)	Low	$16.50
Seroflo 125 Inhaler	125 mcg with 25 mcg per puff	500 mcg (2 puffs twice daily)	Medium	$18.75
Seroflo 250 Inhaler	250 mcg with 25 mcg per puff	1,000 mcg (2 puffs twice daily)	High	$25.50
Seroflo 100 Rotacaps	100 mcg with 50 mcg per capsule	200 mcg (1 capsule twice daily)	Low	$13.00
Seroflo 250 Rotacaps	250 mcg with 50 mcg per capsule	500 mcg (1 capsule twice daily)	Medium	$15.00
Seroflo 500 Rotacaps	500 mcg with 50 mcg per capsule	1,000 mcg (1 capsule twice daily)	High	$17.10
Foracort 100 Inhaler	Budesonide 100 mcg, formoterol 6 mcg per puff	400 mcg (2 puffs twice daily)	Low	$9.00
Foracort 200 Inhaler	200 mcg with 6 mcg per puff	800 mcg (2 puffs twice daily)	Medium	$21.00
Foracort 400 Rotacap	400 mcg with 6 mcg per capsule	800 mcg (1 capsule twice daily)	Medium	$20.00
Symbicort 160/4.5 Turbuhaler	160 mcg with 4.5 mcg delivered (200/6 metered)	800 mcg metered (2 inhalations twice daily)	Medium	$30.00

The regimens in that table are common starting points used to place each product in a band. They are not dosing instructions. On maintenance and reliever therapy the budesonide total also rises on days when reliever doses are taken, which is the intended design.

The LABA safety question and why the boxed warning came off

From 2003 until December 2017, every US inhaler containing a long-acting beta agonist carried a boxed warning about asthma-related death. It traced back to the Salmeterol Multicenter Asthma Research Trial, which added salmeterol to usual care at a time when many patients were not also taking an inhaled steroid (PMID: 16424409). The open question was whether the risk remained when the bronchodilator came locked in the same inhaler as a steroid.

In 2011 the FDA required the manufacturers to answer it with large 26-week trials comparing each combination with its steroid alone. The program enrolled 41,297 patients across four trials. The two that matter here:

	Fluticasone with salmeterol vs fluticasone (AUSTRI)	Budesonide with formoterol vs budesonide
Patients randomized	11,679	11,693
Serious asthma-related events (death, intubation or hospitalization)	36 events in 34 patients vs 38 events in 33 patients	43 patients vs 40 patients
Hazard ratio for a serious event	1.03 (95% CI 0.64 to 1.66)	1.07 (95% CI 0.70 to 1.65)
Effect on severe exacerbations	8% vs 10% had one; hazard ratio 0.79	Hazard ratio 0.84 (16.5% lower risk)

Both combinations met the pre-specified non-inferiority margin for serious events and both reduced exacerbations compared with the steroid alone (PMID: 26949137, PMID: 27579635). There were no asthma deaths in AUSTRI. In the budesonide trial there were two, both in the combination arm. On the strength of these results the FDA removed the boxed warning from all inhaled corticosteroid and long-acting beta agonist combinations in December 2017.

Two caveats. Both trials excluded patients with a history of life-threatening asthma, so the reassurance applies most firmly to the kind of patient who was enrolled. And each trial compared a combination with its own steroid, not with the other combination, so they settle safety rather than which pairing is better.

The rule that did not change

A long-acting beta agonist on its own, without an inhaled steroid, is still not an acceptable asthma treatment. Combination inhalers solve this by design, because the two drugs cannot be separated. The risk returns when someone uses a stand-alone salmeterol or formoterol inhaler and lets the steroid lapse, or stops a combination inhaler because of cost and keeps only a bronchodilator going. If cost is forcing a choice between components, the steroid is the component that protects against attacks, and the decision belongs with a prescriber rather than with whichever inhaler feels more effective.

Side effects, split by component

Most side effects are shared, because most come from the drug class rather than the specific molecule.

From the steroid, locally: oral thrush, hoarseness and throat irritation. Oropharyngeal candidiasis and hoarseness were among the most common effects in salmeterol and fluticasone trials, each reported in 5 percent of patients or fewer, alongside headache, palpitations, tremor and dizziness (PMID: 10400406). Rinsing the mouth and spitting after every dose reduces the local effects with either inhaler.

From the bronchodilator: tremor, palpitations and headache, dose related and usually settling over the first weeks. In budesonide and formoterol trials the most commonly reported effects were respiratory infection, pharyngitis and cough, and no adverse effects on pulse rate, blood pressure or serum potassium were reported for the combination (PMID: 11217872). On maintenance and reliever therapy, formoterol exposure rises on high-use days, so tremor after a cluster of reliever puffs is expected pharmacology and a prompt to check the daily ceiling, not an allergy.

One pharmacokinetic oddity belongs to salmeterol alone. It is formulated as the xinafoate salt, and the xinafoate portion has a half-life of 12 to 15 days and builds up in plasma with regular use. It has no apparent pharmacological activity, so this matters for interpreting research blood levels rather than for patients (PMID: 11825095).

An interaction that matters for both

Fluticasone, salmeterol and budesonide are all metabolized by the liver enzyme CYP3A4 (PMID: 11825095 for salmeterol). Strong inhibitors of that enzyme, including ritonavir and cobicistat-boosted HIV regimens, ketoconazole, itraconazole and clarithromycin, can push blood levels well above what the inhaled dose was designed to produce. The Advair label advises against combining it with strong CYP3A4 inhibitors because of increased systemic steroid and cardiovascular effects, and Cushing's syndrome with adrenal suppression has been reported when inhaled fluticasone was combined with ritonavir. The Symbicort label advises caution with the same class of drugs. Anyone starting one of these medicines while on a combination inhaler should tell the prescriber which inhaler it is.

Non-selective beta blockers, including some glaucoma eye drops, can blunt the bronchodilator and provoke bronchospasm in people with asthma, and both labels flag them.

Where Maxiflo and Fullform fit

Two other Cipla combinations sit between Seroflo and Foracort and are often mistaken for one or the other.

Maxiflo pairs fluticasone propionate with formoterol, the fast bronchodilator. On pharmacology alone it looks as if it should work as a reliever, but the maintenance and reliever evidence was generated with budesonide and formoterol and with beclometasone and formoterol, not with fluticasone and formoterol. Treat Maxiflo as a twice-daily maintenance inhaler with a separate reliever unless a prescriber has a specific reason to do otherwise.

Fullform pairs beclometasone with formoterol, the pairing sold in Europe as Fostair. The maintenance and reliever data for that pairing come from the extrafine formulations, not from capsule devices, so applying the regimen to a Rotacap is a clinical judgment. Beclometasone doses are not comparable with budesonide or fluticasone microgram for microgram, so any switch needs the daily band worked out again.

COPD is a separate question

Both pairings are licensed for chronic obstructive pulmonary disease in some strengths, but in COPD neither is the first choice any more. The GOLD 2025 report recommends a long-acting muscarinic antagonist with a long-acting beta agonist as the preferred starting treatment for most symptomatic patients, and adds an inhaled steroid only for patients who have exacerbations and a blood eosinophil count of 300 cells per microliter or more. Inhaled steroids raise pneumonia risk in COPD and help mainly the subgroup with eosinophilic inflammation. Our tiotropium guide covers the muscarinic antagonist side of that decision.

For COPD patients already on a steroid combination, a one-year open-label trial compared budesonide and formoterol maintenance and reliever therapy with fixed fluticasone and salmeterol 500/50 and found identical exacerbation rates, 1.32 per year in each arm, with the maintenance and reliever arm using roughly half the steroid dose (PMID: 36725331). An Indian expert panel has argued the other way for salmeterol in COPD patients with cardiovascular disease, on the basis that it is a highly selective partial agonist with a reassuring cardiac safety record, and that this outweighs its slower onset in that group (PMID: 35057598). Both are defensible positions for different patients.

Switching from one to the other

Switching is common, usually for cost or availability, and three things change at once.

• The steroid dose. Work out the new daily total and check which band it lands in. Moving from Seroflo 250 aerosol at two puffs twice daily to Foracort 200 at two puffs twice daily is a move from the high band to the medium band, which may or may not be intended.
• The reliever plan. Moving from Seroflo to Foracort on a maintenance and reliever regimen means the same inhaler becomes the reliever. Moving the other way means a separate reliever becomes essential again and the controller must never be used for relief.
• The device. A change from an aerosol inhaler to a Rotacap or Turbuhaler changes the technique and the amount of drug reaching the lungs. Our guide to choosing between Rotacaps, inhalers and respules covers what changes.

Asthma that was controlled before a switch and is not controlled a few weeks after it is a reason to review dose and technique with the prescriber, not a reason to add puffs.

A straight answer

If you have had an attack needing oral steroids or emergency care in the past year, or you reach for a reliever more than a couple of times a week, the evidence favors budesonide with formoterol used as maintenance and reliever therapy. The benefit is fewer severe exacerbations at a similar or lower total steroid dose.

If you are stable on Advair or Seroflo, rarely flare and take it reliably, there is no strong reason to switch. Day-to-day control is similar, and the AHEAD trial could not show a difference in time to first attack against high-dose fluticasone and salmeterol.

If a variable dosing plan would be hard to follow, a fixed twice-daily regimen of either pairing with a separate reliever is a legitimate choice.

Whatever the choice, Seroflo and Advair are never relievers, and no combination inhaler replaces a written plan for what to do when symptoms escalate. Where these inhalers sit alongside tablets and relievers is set out on our asthma treatment overview, and our montelukast guide covers the main oral alternative.

Medical disclaimer

This article is educational and does not replace advice from a qualified healthcare professional. Fluticasone with salmeterol and budesonide with formoterol are prescription medicines in the United States, United Kingdom, Canada and Australia. The regimens shown are used to compare products and are not dosing instructions. Maintenance and reliever therapy, including its daily maximum, must be set by a prescriber. Worsening asthma, or a reliever that is no longer working, needs urgent medical assessment.

References

• Palmqvist M et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997. PubMed PMID: 9426083.
• Kuna P et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations (COMPASS). Int J Clin Pract 2007. PubMed PMID: 17362472.
• Bousquet J et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone (AHEAD). Respir Med 2007;101:2437-2446.
• Effectiveness and safety of budesonide/formoterol in asthma: a systematic review. PubMed PMID: 42450874.
• Stempel DA et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone (AUSTRI). N Engl J Med 2016. PubMed PMID: 26949137.
• Peters SP et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. N Engl J Med 2016. PubMed PMID: 27579635.
• Seymour SM et al. Inhaled corticosteroids and LABAs: removal of the FDA's boxed warning. N Engl J Med 2018.
• Nelson HS et al. The Salmeterol Multicenter Asthma Research Trial. Chest 2006. PubMed PMID: 16424409.
• Salmeterol/fluticasone propionate combination. PubMed PMID: 10400406.
• Inhaled budesonide/formoterol combination. PubMed PMID: 11217872.
• Clinical pharmacokinetics of salmeterol. PubMed PMID: 11825095.
• Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. PubMed PMID: 36725331.
• Salmeterol-fluticasone: the role revisited. PubMed PMID: 35057598.
• The role of ICS-containing rescue therapy versus SABA alone in asthma management today. PubMed PMID: 38237858.
• Global Initiative for Asthma, low, medium and high daily inhaled corticosteroid doses for adults and adolescents.
• NAEPP Expert Panel Working Group, 2020 Focused Updates to the Asthma Management Guidelines.
• Global Initiative for Chronic Obstructive Lung Disease, 2025 report, initial pharmacological treatment.
• FDA prescribing information, Advair HFA and Diskus, and Symbicort: drug interactions sections.

Related reading on asthma treatment

For the full maintenance and reliever regimen see our budesonide with formoterol guide. For relievers, see salbutamol compared with levosalbutamol. Device choice is covered in Rotacaps vs inhaler vs respules, and add-on bronchodilator treatment in our tiotropium guide. The full range is on our asthma and respiratory medicines page.